Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027365 · ClinicalTrials.gov registry record · Phase 1
An Investigational Combination Vaccine Given to People Who Are Not Infected With HIV
A Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
- 15
- Study locations
NCT00027365: Completed Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00027365 is a Phase 1 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 84 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (81% lower). The trial reports 15 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00027365, a Phase 1 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to see if the investigational vaccines NefTat and gp120w61d are safe and tolerable in humans and to see how the immune system responds to the vaccines. There have been advances in the treatment and prevention of HIV, but the spread of HIV/AIDS is getting worse. HIV/AIDS is the main infectious cause of death in the world. A vaccine to prevent HIV disease is the best way to try to deal with this situation. Several vaccine products have been tested, but only 2 are still in trial. There is a need for a new product.
Conditions Studied
Interventions
- BIOLOGICAL Combination Vaccine (NefTat and gp120W61D) Formulated with AS02A
- BIOLOGICAL NefTat
- DRUG AS02A Adjuvant
- BIOLOGICAL gp120W61D
Study Locations (15)
New York
- NY Blood Ctr./Union Square CRS - New York
- HIV Prevention & Treatment CRS - New York
- Univ. of Rochester HVTN CRS - Rochester
- NY Blood Ctr./Bronx CRS - The Bronx
Maryland
- Johns Hopkins Bloomberg School of Public Health,Ctr for Immunization Research, Project SAVE-Baltimore - Baltimore
- Project Brave HIV Vaccine CRS - Baltimore
Massachusetts
- Brigham and Women's Hosp. CRS - Boston
- Fenway Community Health Clinical Research Site (FCHCRS) - Boston
Alabama
- Alabama Vaccine CRS - Birmingham
California
- San Francisco Vaccine and Prevention CRS - San Francisco
Missouri
- Saint Louis Univ. School of Medicine, HVTU - St Louis
Rhode Island
- Miriam Hospital's HVTU - Providence
Tennessee
- Vanderbilt Vaccine CRS - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Est. Completion | 2003-06 |
| Phase | Phase 1 |
What the finished NCT00027365 record still lists
NCT00027365 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (81% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 4 interventions - of which Combination Vaccine (NefTat and gp120W61D) Formulated with AS02A is the first listed.
NCT00027365 lists 15 locations in 10 states (New York, Maryland, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT00027365 about?
NCT00027365 is a clinical study titled "An Investigational Combination Vaccine Given to People Who Are Not Infected With HIV". The purpose of this study is to see if the investigational vaccines NefTat and gp120w61d are safe and tolerable in humans and to see how the immune system responds to the vaccines. There have been advances in the treatment and prevention of HIV, but the spread of HIV/AIDS is getting worse. HIV/AIDS...
What is the current status of trial NCT00027365?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. Estimated completion is 2003-06.
What conditions does trial NCT00027365 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00027365?
The interventions under investigation include: Combination Vaccine (NefTat and gp120W61D) Formulated with AS02A (BIOLOGICAL), NefTat (BIOLOGICAL), AS02A Adjuvant (DRUG), gp120W61D (BIOLOGICAL).
Who is sponsoring clinical trial NCT00027365?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00027365 being conducted?
This trial has 15 study locations across Alabama, California, Maryland, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00027365's enrollment target sits among peer trials
84 296th of 542 higher than 247 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma